Prevention of Radiation-Induced Breast Cancer by Amifostine
Abstract
Exposure to ionizing radiation at doses used in cancer radiotherapy and diagnostic radiology can increase breast cancer risk in women less than 45 years of age. Amifostine is a currently used cytoprotective agent. In addition to its cytoprotective effect amifostine has been reported to inhibit radiation-induced mutagenesis in cultured cells and to protect against radiation-induced tumorigenesis in rodent model systems. This project is a pre-clinical study designed to determine if amifostine might be effective in preventing breast cancer initiation by medical exposures to ionizing radiation. The experiments will determine if amifostine is protective in a murine model of breast cancer initiation and if so determine the optimum dose route and timing for its administration. The first years objective was to test a high dose of amifostine administered I.P. prior to irradiation for reduction of ductal dysplasia in an outgrowth assay. Between September 2002 and May 2003 twenty-two donor mice were irradiated and 412 mammary fat pads were transplanted with mammary epithelial cells from these irradiated donors. Of these 306 were harvested and examined as whole mounts. No dysplasias were seen but due to the low outgrowth frequency no conclusions were drawn yet on the effectiveness of amifostine. In August 2003 the PI moved from M.D Anderson Cancer Center to Colorado State University and experienced a delay of nearly 2 years in having the grant transferred. During this time breeding pairs of mice aged past their useful age. The project resumed in August 2005 with the establishment of a new breeding colony. Since that time an additional 116 mice have been transplanted (232 fat pads) and outgrowths have been prepared for histology.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2006
- Accession Number
- ADA457691
Entities
People
- Michael M. Weil
Organizations
- Colorado State University